Simultaneous quantification of apolipoprotein A-I and apolipoprotein B by liquid-chromatography-multiple-reaction-monitoring mass spectrometry

Clinical Chemistry

Volumn 56, Issue 12, 2010, Pages 1804-1813

  Agger, Sean A ^a   Marney, Luke C ^a   Hoofnagle, Andrew N ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; PEPTIDE; TRIFLUOROETHANOL; UREA;

ALKYLATION; ARTICLE; CALIBRATION; EVALUATION; HUMAN; IMMUNOASSAY; INTERMETHOD COMPARISON; LIQUID CHROMATOGRAPHY; LIQUID CHROMATOGRAPHY MULTIPLE REACTION MONITORING MASS SPECTROMETRY; MASS SPECTROMETRY; NEPHELOMETRY; PROTEIN DEGRADATION; PROTEIN DENATURATION; PROTEIN DETERMINATION; QUANTITATIVE ANALYSIS; REDUCTION; REVERSED PHASE LIQUID CHROMATOGRAPHY; VALIDATION PROCESS;

APOLIPOPROTEIN A-I; APOLIPOPROTEINS B; BIOLOGICAL MARKERS; CALIBRATION; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; HUMANS; IMMUNOASSAY; NEPHELOMETRY AND TURBIDIMETRY; PROTEIN DENATURATION; REPRODUCIBILITY OF RESULTS; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; TANDEM MASS SPECTROMETRY; TRIFLUOROETHANOL; UREA;

EID: 78649834299     PISSN: 00099147     EISSN: 15308561     Source Type: Journal    
DOI: 10.1373/clinchem.2010.152264     Document Type: Article

References (35)

1. Hoofnagle AN, Wener MH. The fundamental flaws of immunoassays and potential solutions using tandem mass spectrometry. J Immunol Methods 2009;347:3-11.
2. Addona TA, Abbatiello SE, Schilling B, Skates SJ, Mani DR, Bunk DM, et al. Multi-site assessment of the precision and reproducibility of multiple reaction monitoring-based measurements of proteins in plasma. Nat Biotechnol 2009;27:633-41.
3. Bondar OP, Barnidge DR, Klee EW, Davis BJ, Klee GG. LC-MS/MS quantification of Zn-alpha2 glycoprotein: a potential serum biomarker for prostate cancer. Clin Chem 2007;53:673-8.
4. Hoofnagle AN, Becker JO, Wener MH, Heinecke JW. Quantification of thyroglobulin, a lowabundance serum protein, by immunoaffinity peptide enrichment and tandem mass spectrometry. Clin Chem 2008;54:1796-804.
5. Kuhn E, Addona T, Keshishian H, Burgess M, Mani DR, Lee RT, et al. Developing multiplexed assays for troponin I and interleukin-33 in plasma by peptide immunoaffinity enrichment and targeted mass spectrometry. Clin Chem 2009;55: 1108-17.
6. Kuhn E, Wu J, Karl J, Liao H, Zolg W, Guild B. Quantification of C-reactive protein in the serum of patients with rheumatoid arthritis using multiple reaction monitoring mass spectrometry and 13C-labeled peptide standards. Proteomics 2004; 4:1175-86.
7. Kuzyk MA, Smith D, Yang J, Cross TJ, Jackson AM, Hardie DB, et al. Multiple reaction monitoring-based, multiplexed, absolute quantitation of 45 proteins in human plasma. Mol Cell Proteomics 2009;8:1860-77.
8. Neubert H, Gale J, Muirhead D. Online high-flow peptide immunoaffinity enrichment and nanoflow liquid chromatography/tandem mass spectrometry: assay development for total salivary pepsin/pepsinogen. Clin Chem 2010;56:1413-23.
9. Whiteaker JR, Zhao L, Anderson L, Paulovich AG. An automated and multiplexed method for high throughput peptide immunoaffinity enrichment and multiple reaction monitoring mass spectrometry-based quantification of protein biomarkers. Mol Cell Proteomics 2010;9:184-96.
10. Ong SE, Mann M. Mass spectrometry-based proteomics turns quantitative. Nat Chem Biol 2005; 1:252-62.
11. Brun V, Masselon C, Garin J, Dupuis A. Isotope dilution strategies for absolute quantitative proteomics. J Proteomics 2009;72:740-9.
12. Elliott MH, Smith DS, Parker CE, Borchers C. Current trends in quantitative proteomics. J Mass Spectrom 2009;44:1637-60.
13. Anderson NL, Anderson NG, Pearson TW, Borchers CH, Paulovich AG, Patterson SD, et al. A human proteome detection and quantitation project. Mol Cell Proteomics 2009;8:883-6.
14. Carr SA, Anderson L. Protein quantitation through targeted mass spectrometry: the way out of biomarker purgatory? Clin Chem 2008;54: 1749-52.
15. Paulovich AG, Whiteaker JR, Hoofnagle AN, Wang P. The interface between biomarker discovery and clinical validation: the tar pit of the protein biomarker pipeline. Proteom Clin Appl 2008;2:1386-402.
16. Contois JH, McConnell JP, Sethi AA, Csako G, Devaraj S, Hoefner DM, Warnick GR. Apolipoprotein B and cardiovascular disease risk: position statement from the AACC Lipoproteins and Vascular Diseases Division Working Group on Best Practices. Clin Chem 2009;55:407-19.
17. Davidson MH. Apolipoprotein measurements: is more widespread use clinically indicated? Clin Cardiol 2009;32:482-6.
18. Holme I, Aastveit AH, Hammar N, Jungner I, Walldius G. Lipoprotein components and risk of congestive heart failure in 84,740 men and women in the Apolipoprotein MOrtality RISk study (AMORIS). Eur J Heart Fail 2009;11:1036-42.
19. Lamarche B, Moorjani S, Lupien PJ, Cantin B, Bernard PM, Dagenais GR, Despres JP. Apolipoprotein A-I and B levels and the risk of ischemic heart disease during a five-year follow-up of men in the Quebec cardiovascular study. Circulation 1996;94:273-8. (Pubitemid 26266109)
20. Barter PJ, Nicholls S, Rye KA, Anantharamaiah GM, Navab M, Fogelman AM. Antiinflammatory properties of HDL. Circ Res 2004;95:764-72.
21. Movva R, Rader DJ. Laboratory assessment of HDL heterogeneity and function. Clin Chem 2008; 54:788-800.
22. Walldius G, Jungner I. The apoB/apoA-I ratio: a strong, new risk factor for cardiovascular disease and a target for lipid-lowering therapy - a review of the evidence. J Intern Med 2006;259: 493-519.
23. Hoofnagle AN, Heinecke JW. Lipoproteomics: using mass spectrometry-based proteomics to explore the assembly, structure, and function of lipoproteins. J Lipid Res 2009;50:1967-75.
24. Kay RG, Gregory B, Grace PB, Pleasance S. The application of ultra-performance liquid chromatography/ tandem mass spectrometry to the detection and quantitation of apolipoproteins in human serum. Rapid Commun Mass Spectrom 2007;21:2585-93.
25. Deutsch EW, Eng JK, Zhang H, King NL, Nesvizhskii AI, Lin B, et al. Human plasma PeptideAtlas. Proteomics 2005;5:3497-500.
26. Meza JE, Miller CA, Fischer SM. Improved tryptic digestion of proteins using 2,2,2-trifluoroethanol (TFE). http://www.chem.agilent. com/Library/posters/Public/5989-1781EN.pdf (Accessed August 2010).
27. Abbatiello SE, Mani DR, Keshishian H, Carr SA. Automated detection of inaccurate and imprecise transitions in peptide quantification by multiple reaction monitoring mass spectrometry. Clin Chem 2010;56:291-305.
28. Rodbard D. Statistical quality control and routine data processing for radioimmunoassays and immunoradiometric assays. Clin Chem 1974;20: 1255-70.
29. La Belle M, McCall MR, Krauss RM, Forte TM. Unique structural properties of apolipoprotein B in low-density lipoproteins produced by several human hepatoma-derived cell lines. Biochim Biophys Acta 1990;1046:288-93.
30. Lopez MF, Rezai T, Sarracino DA, Prakash A, Krastins B, Athanas M, et al. Selected reaction monitoring-mass spectrometric immunoassay responsive to parathyroid hormone and related variants. Clin Chem 2010;56:281-90.
31. Anderson NL, Anderson NG, Haines LR, Hardie DB, Olafson RW, Pearson TW. Mass spectrometric quantitation of peptides and proteins using Stable Isotope Standards and Capture by Anti- Peptide Antibodies (SISCAPA). J Proteome Res 2004;3:235-44.
32. Hoofnagle AN. Quantitative clinical proteomics by liquid chromatography-tandem mass spectrometry: assessing the platform. Clin Chem 2010;56:161-4.
33. Hoofnagle AN. Peptide lost and found: internal standards and the mass spectrometric quantification of peptides. Clin Chem 2010;56:1515-17.
34. Barr JR, Maggio VL, Patterson DG Jr, Cooper GR, Henderson LO, Turner WE, et al. Isotope dilution-mass spectrometric quantification of specific proteins: model application with apolipoprotein A-I. Clin Chem 1996;42:1676-82.
35. R Development Core Team. R: A language and environment for statistical computing [computer program]. Vienna (Austria): R Foundation for Statistical Computing; 2008.